Agricultural Inputs
Compare Stocks
5 / 10Stock Comparison
BIOX vs CTVA vs FMC vs CF vs MOS
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
Agricultural Inputs
Agricultural Inputs
Agricultural Inputs
BIOX vs CTVA vs FMC vs CF vs MOS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Agricultural Inputs | Agricultural Inputs | Agricultural Inputs | Agricultural Inputs | Agricultural Inputs |
| Market Cap | $30M | $53.08B | $1.71B | $18.24B | $7.27B |
| Revenue (TTM) | $318M | $17.89B | $3.43B | $7.41B | $11.68B |
| Net Income (TTM) | $-53M | $1.16B | $-2.50B | $1.76B | $1.22B |
| Gross Margin | 39.1% | 33.5% | 35.3% | 40.4% | 16.5% |
| Operating Margin | 0.2% | 13.8% | -59.5% | 35.7% | 9.9% |
| Forward P/E | — | 21.6x | 7.7x | 8.4x | 15.7x |
| Total Debt | $277M | $2.58B | $4.20B | $3.95B | $760M |
| Cash & Equiv. | $33M | $4.52B | $585M | $1.98B | $277M |
BIOX vs CTVA vs FMC vs CF vs MOS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bioceres Crop Solut… (BIOX) | 100 | 7.1 | -92.9% |
| Corteva, Inc. (CTVA) | 100 | 289.5 | +189.5% |
| FMC Corporation (FMC) | 100 | 13.9 | -86.1% |
| CF Industries Holdi… (CF) | 100 | 404.3 | +304.3% |
| The Mosaic Company (MOS) | 100 | 189.5 | +89.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOX vs CTVA vs FMC vs CF vs MOS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BIOX lags the leaders in this set but could rank higher in a more targeted comparison.
CTVA ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.29, Low D/E 10.6%, current ratio 1.43x
- Beta 0.29, yield 0.9%, current ratio 1.43x
- Beta 0.29 vs BIOX's 1.94, lower leverage
FMC is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 7 yrs, beta 1.63, yield 17.0%
- Lower P/E (7.7x vs 15.7x)
- 17.0% yield, 7-year raise streak, vs MOS's 4.2%, (1 stock pays no dividend)
CF carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 19.3%, EPS growth 33.1%, 3Y rev CAGR -14.1%
- 338.1% 10Y total return vs CTVA's 186.7%
- PEG 0.19 vs CTVA's 1.81
- 19.3% revenue growth vs BIOX's -28.3%
Among these 5 stocks, MOS doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.3% revenue growth vs BIOX's -28.3% | |
| Value | Lower P/E (7.7x vs 15.7x) | |
| Quality / Margins | 23.7% margin vs FMC's -72.9% | |
| Stability / Safety | Beta 0.29 vs BIOX's 1.94, lower leverage | |
| Dividends | 17.0% yield, 7-year raise streak, vs MOS's 4.2%, (1 stock pays no dividend) | |
| Momentum (1Y) | +49.6% vs BIOX's -88.5% | |
| Efficiency (ROA) | 12.4% ROA vs FMC's -23.0%, ROIC 18.7% vs -21.2% |
BIOX vs CTVA vs FMC vs CF vs MOS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BIOX vs CTVA vs FMC vs CF vs MOS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CF leads in 3 of 6 categories
BIOX leads 1 • FMC leads 1 • CTVA leads 0 • MOS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CF leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CTVA is the larger business by revenue, generating $17.9B annually — 56.2x BIOX's $318M. CF is the more profitable business, keeping 23.7% of every revenue dollar as net income compared to FMC's -72.9%. On growth, CF holds the edge at +19.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $318M | $17.9B | $3.4B | $7.4B | $11.7B |
| EBITDAEarnings before interest/tax | $21M | $3.4B | -$1.9B | $3.5B | $2.2B |
| Net IncomeAfter-tax profit | -$53M | $1.2B | -$2.5B | $1.8B | $1.2B |
| Free Cash FlowCash after capex | $37M | $2.1B | -$91M | $1.6B | -$535M |
| Gross MarginGross profit ÷ Revenue | +39.1% | +33.5% | +35.3% | +40.4% | +16.5% |
| Operating MarginEBIT ÷ Revenue | +0.2% | +13.8% | -59.5% | +35.7% | +9.9% |
| Net MarginNet income ÷ Revenue | -16.6% | +6.5% | -72.9% | +23.7% | +10.5% |
| FCF MarginFCF ÷ Revenue | +11.5% | +11.5% | -2.7% | +21.9% | -4.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.4% | +11.0% | -4.1% | +19.4% | -7.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -37.3% | +12.6% | -17.8% | +115.1% | +3.8% |
Valuation Metrics
BIOX leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 5.9x trailing earnings, MOS trades at a 88% valuation discount to CTVA's 49.4x P/E. Adjusting for growth (PEG ratio), CF offers better value at 0.30x vs CTVA's 4.14x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $30M | $53.1B | $1.7B | $18.2B | $7.3B |
| Enterprise ValueMkt cap + debt − cash | $274M | $51.1B | $5.3B | $20.2B | $7.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.58x | 49.42x | -0.77x | 13.24x | 5.90x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.57x | 7.74x | 8.41x | 15.68x |
| PEG RatioP/E ÷ EPS growth rate | — | 4.14x | — | 0.30x | 0.34x |
| EV / EBITDAEnterprise value multiple | 20.01x | 13.38x | — | 6.19x | 3.59x |
| Price / SalesMarket cap ÷ Revenue | 0.09x | 3.05x | 0.49x | 2.57x | 0.62x |
| Price / BookPrice ÷ Book value/share | 0.10x | 2.18x | 0.82x | 2.48x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 0.85x | 18.86x | — | 10.12x | — |
Profitability & Efficiency
CF leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CF delivers a 22.3% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-82 for FMC. MOS carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to FMC's 2.00x. On the Piotroski fundamental quality scale (0–9), CF scores 8/9 vs FMC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -16.7% | +4.6% | -82.3% | +22.3% | +10.0% |
| ROA (TTM)Return on assets | -6.7% | +2.7% | -23.0% | +12.4% | +5.0% |
| ROICReturn on invested capital | -0.5% | +8.5% | -21.2% | +18.7% | +6.1% |
| ROCEReturn on capital employed | -0.8% | +8.6% | -25.9% | +18.3% | +5.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 2 | 8 | 7 |
| Debt / EquityFinancial leverage | 0.94x | 0.11x | 2.00x | 0.51x | 0.06x |
| Net DebtTotal debt minus cash | $244M | -$1.9B | $3.6B | $2.0B | $483M |
| Cash & Equiv.Liquid assets | $33M | $4.5B | $585M | $2.0B | $277M |
| Total DebtShort + long-term debt | $277M | $2.6B | $4.2B | $3.9B | $760M |
| Interest CoverageEBIT ÷ Interest expense | -0.07x | 5.82x | -0.24x | 16.31x | 8.81x |
Total Returns (Dividends Reinvested)
CF leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CF five years ago would be worth $23,091 today (with dividends reinvested), compared to $317 for BIOX. Over the past 12 months, CF leads with a +49.6% total return vs BIOX's -88.5%. The 3-year compound annual growth rate (CAGR) favors CF at 22.6% vs BIOX's -64.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -65.0% | +17.0% | -4.0% | +48.8% | -7.6% |
| 1-Year ReturnPast 12 months | -88.5% | +27.7% | -57.1% | +49.6% | -24.6% |
| 3-Year ReturnCumulative with dividends | -95.3% | +40.8% | -82.5% | +84.1% | -32.7% |
| 5-Year ReturnCumulative with dividends | -96.8% | +68.3% | -80.2% | +130.9% | -27.9% |
| 10-Year ReturnCumulative with dividends | -95.1% | +186.7% | -26.8% | +338.1% | +14.9% |
| CAGR (3Y)Annualised 3-year return | -64.0% | +12.1% | -44.0% | +22.6% | -12.4% |
Risk & Volatility
Evenly matched — CTVA and CF each lead in 1 of 2 comparable metrics.
Risk & Volatility
CF is the less volatile stock with a -0.62 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CTVA currently trades 92.3% from its 52-week high vs BIOX's 9.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.94x | 0.29x | 1.63x | -0.62x | 0.52x |
| 52-Week HighHighest price in past year | $5.18 | $85.63 | $44.78 | $141.96 | $38.23 |
| 52-Week LowLowest price in past year | $0.35 | $60.54 | $12.17 | $75.42 | $22.74 |
| % of 52W HighCurrent price vs 52-week peak | +9.1% | +92.3% | +30.5% | +83.6% | +59.9% |
| RSI (14)Momentum oscillator 0–100 | 44.6 | 53.3 | 43.4 | 47.0 | 42.7 |
| Avg Volume (50D)Average daily shares traded | 804K | 3.4M | 3.2M | 4.9M | 9.5M |
Analyst Outlook
FMC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CTVA as "Buy", FMC as "Hold", CF as "Buy", MOS as "Hold". Consensus price targets imply 36.4% upside for MOS (target: $31) vs -8.3% for CF (target: $109). For income investors, FMC offers the higher dividend yield at 17.01% vs CTVA's 0.89%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | — | $88.17 | $15.58 | $108.89 | $31.25 |
| # AnalystsCovering analysts | — | 37 | 42 | 41 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | +0.9% | +17.0% | +1.7% | +4.2% |
| Dividend StreakConsecutive years of raises | — | 5 | 7 | 0 | 1 |
| Dividend / ShareAnnual DPS | — | $0.71 | $2.33 | $2.01 | $0.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.1% | +2.0% | +0.1% | 0.0% | 0.0% |
CF leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BIOX leads in 1 (Valuation Metrics). 1 tied.
BIOX vs CTVA vs FMC vs CF vs MOS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BIOX or CTVA or FMC or CF or MOS a better buy right now?
For growth investors, CF Industries Holdings, Inc.
(CF) is the stronger pick with 19. 3% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). The Mosaic Company (MOS) offers the better valuation at 5. 9x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BIOX or CTVA or FMC or CF or MOS?
On trailing P/E, The Mosaic Company (MOS) is the cheapest at 5.
9x versus Corteva, Inc. at 49. 4x. On forward P/E, FMC Corporation is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CF Industries Holdings, Inc. wins at 0. 19x versus Corteva, Inc. 's 1. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — BIOX or CTVA or FMC or CF or MOS?
Over the past 5 years, CF Industries Holdings, Inc.
(CF) delivered a total return of +130. 9%, compared to -96. 8% for Bioceres Crop Solutions Corp. (BIOX). Over 10 years, the gap is even starker: CF returned +338. 1% versus BIOX's -95. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BIOX or CTVA or FMC or CF or MOS?
By beta (market sensitivity over 5 years), CF Industries Holdings, Inc.
(CF) is the lower-risk stock at -0. 62β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately -411% more volatile than CF relative to the S&P 500. On balance sheet safety, The Mosaic Company (MOS) carries a lower debt/equity ratio of 6% versus 2% for FMC Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — BIOX or CTVA or FMC or CF or MOS?
By revenue growth (latest reported year), CF Industries Holdings, Inc.
(CF) is pulling ahead at 19. 3% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: The Mosaic Company grew EPS 605. 5% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, BIOX leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BIOX or CTVA or FMC or CF or MOS?
CF Industries Holdings, Inc.
(CF) is the more profitable company, earning 20. 5% net margin versus -64. 6% for FMC Corporation — meaning it keeps 20. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CF leads at 33. 4% versus -54. 4% for FMC. At the gross margin level — before operating expenses — CTVA leads at 43. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BIOX or CTVA or FMC or CF or MOS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CF Industries Holdings, Inc. (CF) is the more undervalued stock at a PEG of 0. 19x versus Corteva, Inc. 's 1. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, FMC Corporation (FMC) trades at 7. 7x forward P/E versus 21. 6x for Corteva, Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MOS: 36. 4% to $31. 25.
08Which pays a better dividend — BIOX or CTVA or FMC or CF or MOS?
In this comparison, FMC (17.
0% yield), MOS (4. 2% yield), CF (1. 7% yield), CTVA (0. 9% yield) pay a dividend. BIOX does not pay a meaningful dividend and should not be held primarily for income.
09Is BIOX or CTVA or FMC or CF or MOS better for a retirement portfolio?
For long-horizon retirement investors, CF Industries Holdings, Inc.
(CF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 62), 1. 7% yield, +338. 1% 10Y return). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CF: +338. 1%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BIOX and CTVA and FMC and CF and MOS?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BIOX is a small-cap quality compounder stock; CTVA is a mid-cap quality compounder stock; FMC is a small-cap income-oriented stock; CF is a mid-cap high-growth stock; MOS is a small-cap deep-value stock. CTVA, FMC, CF, MOS pay a dividend while BIOX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.